Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Evolution of delayed resistance to immunotherapy in a melanoma responder

Nature Medicine(2021)10.1038/s41591-021-01331-8Source: DataRank Database

Evolution of delayed resistance to immunotherapy in a melanoma responder is a research paper published in Nature Medicine (2021). On theSindex it has a DataRank of 3.6. It has been cited 137 times, with 111 citing works in its 1-hop citation network.

N/A

3.6DataRank · unranked

Scored on demand from live citation data

Open Access137 citations · 111 citing works in its network

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (22 grants)Impact (FWCI 6.89)OA: greenTopics (44)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 21%Citation Network 79%

Base Score Contribution

0.739

From this paper's citation signal

Citation Network Contribution

2.8

From 91 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 111 citers.

SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies
Nature Medicine202177 citations18 referencesContributes 0.242
Heterogeneous PD-L1 expression in metastases impacts immunotherapy response
EBioMedicine20239 citations10 referencesContributes 0.230
The Hitchhiker’s Guide across a Waddington’s landscape of melanoma
Developmental Cell20223 citations11 referencesContributes 0.126
Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post–PD-1 Immunotherapy
Cancer Immunology Research202218 citations26 referencesContributes 0.113
Isoliquiritigenin suppresses the progression of malignant melanoma via targeting H2A.Z.1-E2F1 pathway
Biochemical Pharmacology202312 citations27 referencesContributes 0.095

Authors (40)

Jia‐Ren Lin ORCID,Emily Robitschek ORCID,Gyulnara G. Kasumova,Alex Heyde,Alvin Shi ORCID

Live enrichment

PubMed:33941922 PMC:PMC8474080 OpenAlex:https://openalex.org/W3157834930

U.S. Department of Defense

Grant: PRCRP WX1XWH-16-1-0119 (CA150619)

Conquer Cancer Foundation

Grant: Young Investigator Award

U.S. Department of Health & Human Services | National Institutes of Health

Grant: K08CA234458

U.S. Department of Health & Human Services | National Institutes of Health

Grant: P01 CA114046; P50 CA174523; U54 CA224070

U.S. Department of Health & Human Services | National Institutes of Health

Grant: U54-CA225088

Doris Duke Charitable Foundation

Grant: Clinical Scientist Development Award

Broad Institute

Grant: BroadNext10

NCI NIH HHS

Grant: K08 CA222663

NCI NIH HHS

Grant: U54 CA224070

Swiss National Science Foundation

Grant: 178022

NCI NIH HHS

Grant: L30 CA220913

NCI NIH HHS

Grant: P50 CA174523

NCI NIH HHS

Grant: P30 CA010815

NCI NIH HHS

Grant: U54 CA225088

NIGMS NIH HHS

Grant: T32 GM087237

NCI NIH HHS

Grant: P01 CA114046

NCI NIH HHS

Grant: R01 CA244975

NHGRI NIH HHS

Grant: T32 HG009495

NCI NIH HHS

Grant: R01 CA227388

Society for Immunotherapy of Cancer

Damon Runyon Cancer Research Foundation

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

FWCI

6.89

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

greenLicense: cc-by-nc

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8474080

publisherhttps://www.nature.com/articles/s41591-021-01331-8.pdf

publisherhttps://www.nature.com/articles/s41591-021-01331-8

journalhttps://doi.org/10.1038/s41591-021-01331-8

Fields of Study

Immunotherapy and Immune Responsesvaccines and immunoinformatics approachesT-cell and B-cell ImmunologyB7-H1 AntigenChromosomes, Human, Pair 15Drug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansImmune Checkpoint InhibitorsImmunotherapyMaleMelanomaNeoplasm MetastasisNeoplasm Recurrence, LocalNerve Tissue ProteinsPhylogenyReceptors, Nerve Growth FactorTumor Microenvironment

MeSH Terms

Immune Checkpoint InhibitorsChromosomes, Human, Pair 15FemaleHumansImmunotherapyMaleMelanomaNeoplasm MetastasisNeoplasm Recurrence, LocalNerve Tissue ProteinsPhylogenyGene Expression Regulation, NeoplasticReceptors, Nerve Growth FactorDrug Resistance, NeoplasmTumor MicroenvironmentB7-H1 Antigen

Keywords

ImmunotherapyMelanomaResistance (ecology)MedicineImmunologyBiologyCancer researchImmune systemEcology

Sustainable Development Goals

SDG 0: Good health and well-being